Details
Published:
InnaraThanks

Innara Health has extended their recognition to BioHealth Innovation, Inc. (BHI) and Ethel Rubin for our significant contributions to Innara Health's journey. BHI is acknowledged for our confidence and insight in introducing Innara Health to the BioHealth Capital Region, while Ethel Rubin is thanked for her expert counsel, candor, and influential role on the Board, along with her valuable network. Our support has played a crucial part in Innara Health's mission to improve the lives of premature newborns and infants.

Details
Published:
Biofactura250

FREDERICK, Md., Oct. 2, 2023 /PRNewswire-PRWeb/ -- BioFactura, Inc. today announced a contract option activation of over $16 million by the Biomedical Advanced Research and Development Authority (BARDA) part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, as part of its prime contract valued at over $77 million for the advanced development of its Smallpox Biodefense Therapeutic. This option will continue to support ongoing product development to include clinical manufacturing of the therapeutic for an upcoming first-in-human Phase 1 trial, which may be funded in a future contract option.

BioFactura's monoclonal antibody-based product has the potential to fulfill an unmet need in preparedness, augment current medical countermeasures and guard against potential resistance. While smallpox was declared eradicated in 1980 by the World Health Organization after an extensive vaccination campaign, the threat of bioterrorism and/or inadvertent release persists.

Details
Published:
Theresa and Rich LinkedIn Post

 

How can patients help shape the future of scientific innovation? What's the vital role of the patient's voice in developing life-changing medicines? In this captivating episode, fresh off her thought-provoking appearance at the 9th Annual BioHealth Capital Region Forum, Dr. Theresa Podrebarac takes us on a journey through the dynamic landscape of autoimmune medicine.

Dr. Podrebarac is a renowned physician scientist with a wealth of expertise in the biotech industry. As the Senior Vice President of Clinical Development at Horizon Therapeutics, she's at the forefront of bringing hope to patients with rare, autoimmune, and severe inflammatory diseases. Join us as we explore pivotal questions:

  • What is Horizon Therapeutics' mission, and what are Dr. Podrebarac's primary responsibilities in this quest for life-changing medicines?
  • How has Dr. Podrebarac's background as a rheumatologist influenced her belief in the importance of the patient's perspective in drug development?
  • Discover Horizon's impressive journey in clinical development, with a sharp focus on autoimmune diseases.
  • Dive into Horizon's global presence and the crucial role of its Maryland operations.
  • What are the clinical goals that will shape the future of autoimmune medicine?

Details
Published:
Newman250

The Greater Washington area has a long history of influential business leaders powering the growth of our region and the strength of their communities. On Dec. 5, the Washington Business Hall of Fame will welcome five such leaders to receive our region’s signature lifetime business achievement award. The Hall of Fame brings these visionaries (the best in business) to the table with the next generation of leaders (the next in business), through an experience that connects and inspires us all.

The 2023 Hall of Fame Laureates are no strangers to media coverage. If you live in the Washington region, chances are you’ve seen their names in headlines for years. What you may not have witnessed is these trailblazers telling their stories in their own words. That’s what this series brings you – the look back, lessons and life advice that these Laureates have to offer based on a lifetime of success.

 

Details
Published:
TedcoAged

COLUMBIA, Md. (September 28, 2023) –TEDCO, Maryland’s economic engine for technology companies, announced a recent $200,000 Seed Funds investment into AGED Diagnostics, a biotechnology company. Previously, AGED Diagnostics received a $250,000 investment from TEDCO’s Builder Fund, a funding opportunity that is under the umbrella of our Social Impact Funds.

“1 in 3 Americans have liver disease, but many remain unaware of it until the disease progresses to a stage when it is no longer curable, patient outcomes are poor and/or healthcare costs are burdensome,” said Rachel Zayas, CEO of AGED Diagnostics. “Thanks to TEDCO’s investment we are able to continue our research and development, working towards a future where liver disease can have early detection.”

Details
Published:
Deka250

GERMANTOWN, Md., Sept. 28, 2023 /PRNewswire/ -- Maryland-based biotech company Deka Biosciences ("Deka") today announced that it has successfully closed a USD $20 Million Series B2 financing with a syndicate of life science investors led by MPM BioImpact, and joined by additional investors including Leaps by Bayer, Lumira Ventures, O-Bio (Echo Investment Capital), Viva BioInnovator, Alexandria Venture Investments, Amana Investments, Plains Ventures, ATEM Capital and CEO John Mumm. The proceeds of the financing will support the advancement of Deka's pipeline and drug product manufacturing as they continue clinical trials following the receipt of a notice to proceed letter from the FDA for their investigational new drug (IND) application to evaluate DK210 (EGFR). Additionally, Detlev Biniszkiewicz, Ph.D. of MPM-BioImpact, will join the Deka board.

Details
Published:
MiniMaryland250

The latest rankings from Genetic Engineering & Biotechnology News  (or GEN) included some long-awaited good news for Maryland: the Biohealth Capital Region (BHCR) had moved up to No. 3 on the publication’s list of the top ten biopharma clusters in the United States.

Leaders in Maryland’s biohealth industry have been working to make the BHCR a “Top 3 by 2023” since back in 2016. In recent years, the region (comprising Maryland, Virginia and Washington, D.C.) has ranked No. 4.

“It’s been an incredible journey working with so many dedicated individuals and organizations in the region over the years to meet this goal,” Rich Bendis, president and CEO of BioHealth Innovation, Inc., said in a statement . “The spirit of collaboration and innovation that defines the BioHealth Capital Region has been the driving force behind this success, and I’m proud to be part of this remarkable community.”

Click here to read the entire article.

Details
Published:
Emmes250

The latest upgrade is part of wider goals to create the industry's first unified digital data platform for decentralized and hybrid trials

ROCKVILLE, Md., Sept. 27, 2023 /PRNewswire/ -- Emmes, a global, full-service Contract Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, announces the addition of telehealth capabilities within Advantage eClinical. The new application means any scheduled visit can become virtual with video calls augmented directly through the platform and patients signing in through their existing participant portal. Advantage eClinical is designed to enable a simple, intuitive experience that fits seamlessly into the everyday lives of study participants and sites.

Details
Published:
RaiseYourReach

If your Maryland-based life sciences company is doing R&D in biotechnology and preparing to raise equity funding, your investors may be eligible to benefit from tax credits from the State of Maryland through the Biotechnology Investment Incentive Tax Credit (BIITC) program. Join the Maryland Department of Commerce on October 2nd to learn about the program benefits and how you can work with your investors to enhance their returns by investing in you. 

Click here to learn more and register.

Details
Published:
Anzu250

Fund III cohort accelerates the energy transition, facilitates discovery of better therapeutics and advances critical industries

ATLANTA & BOSTON & SAN DIEGO & TAMPA, Fla. & WASHINGTON–()–Anzu Partners, an investment firm delivering capital and strategic support to early-stage breakthrough technology companies, today announced it has raised more than $200 million at the close of its third venture capital fund.

Fund III was established to invest in companies developing next-generation solutions in clean technology, industrial innovations, and life sciences. Investors in Fund III include new and returning public and private institutions, single and multifamily offices, and accredited investors across the U.S. and overseas.

Details
Published:
Theradaptive250

FREDERICK, Md., September 26, 2023: Today, Theradaptive, a leading biopharmaceutical company using protein engineering to create targeted therapeutics, has been awarded a U.S. Department of Defense (DOD) Clinical Trial Award of up to $7.4M with options, subject to FDA approval to begin phase I/II clinical studies. Awarded through the DOD’s Peer Reviewed Medical Research Program (PRMRP), the award recognizes the scientific merit of Theradaptive’s work in targeted regenerative therapeutics to create safer and more efficacious treatments for patients with conditions such as spinal degenerative disc disease, orthopedic trauma, and craniomaxillofacial and dental repair.

The Clinical Trial Award is aimed at providing assistance to companies implementing clinical trials for biologics or medical devices focused on improving the patient outcomes of military service members and veterans. This award will help Theradaptive scale up the production of its OsteoAdapt regenerative therapeutic product for spine and trauma repair and will become clinically available upon initiation of first in human clinical trials in early 2024.

Details
Published:
BHCRRichy

The BioHealth Capital Region continued its tradition of fostering innovation, collaboration, and growth in the life sciences sector with its series of events in 2023. The highlights included the 9th Annual BioHealth Capital Region Forum, the 8th Annual BioHealth Capital Region Crab Trap, and the 6th Annual BioHealth Capital Region Investment Conference, bringing together industry, academic, government, entrepreneurs, and investors.

Details
Published:
WomenBuildingBio

Virginia Bio’s Women Building Bio Conference celebrates the contribution of women to the life sciences in the Commonwealth and beyond. The 8th annual conference theme, Building Better, will prompt us to explore how life sciences contribute to building a better future and highlight the increasingly significant role of women in it.

 

Details
Published:
BHI250

Opening – Technical Writer and Project Manager

BioHealth Innovation (BHI) is an innovation intermediary that facilitates commercialization of emerging technologies in the BioHealth Capital Region (Maryland, DC and Virginia).

BHI is seeking a Technical Writer and Project Manager to join its team remotely. This position provides the opportunity to leverage scientific knowledge to evaluate the commercial potential of emerging technologies and provide recommendations on go-to-market strategies. This is a customer facing role with a focus on supporting clients in the development of commercial analyses and federal grant proposals. This position is geared toward an early-career scientist with extensive writing experience and a history of funded grant proposals.

This position could be either employee or part time contractor depending on applicants experience and availability. Compensation will be competitive but dependent based on experience.

Details
Published:
tedconataur

COLUMBIA, Md. (September 25, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a recent $200,000 investment into Natáur. This recent investment came from TEDCO’s Social Impact Funds.

“Natáur is creating bio-based taurine—an essential nutrient for brain development, healthy aging, heart health, and microbiome balance,” said Kathleen Turano, Natáur CEO. "Taurine occurs naturally in animal products but it is missing in plants. With shifts towards more plant-based diets, taurine will need to be added as an ingredient or taken as a supplement to maintain healthy taurine levels. With TEDCO’s investment, we move closer to launching our bio-based taurine."

Details
Published:
Luminoah 250

Luminoah Wins 8th Annual Crab Trap Competition at BioHealth Capital Region Forum

Rockville, MD, September 22, 2023 — Luminoah, a MedTech startup located in Charlottesville, VA, dedicated to improving the lives of people requiring enteral feeding, emerged as the top company at the 8th Annual Crab Trap Competition, held as part of this year’s BioHealth Capital Region Forum. The event, which took place on September 20th, showcased Luminoah's innovative wearable system, designed to optimize compliance and clinical outcomes through the integration of durable medical equipment, consumable nutrition pouches, and remote patient monitoring.

Neal Piper, Founder & CEO of Luminoah, delivered an outstanding presentation highlighting the company's groundbreaking technology. Luminoah's wearable system represents a significant advancement in the field of enteral feeding, offering an innovative solution to enhance patient care.

Details
Published:
UnitedThera250

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the achievement of two milestones for its xenotransplantation programs in September: the second transplant of a UHeart™ xenoheart into a living person, and a 61-day study of the UThymoKidney™ xenokidney and thymus in a human pre-clinical model.

United Therapeutics’ organ manufacturing efforts consist of seven investigational programs: xenoheart, xenokidney, xenothymokidney, regenerative lungs, 3D-printed lungs, 3D-printed livers, and 3D-printed kidneys. These groundbreaking programs are intended to address the ongoing shortage of transplantable organs for patients with end stage organ disease.

Details
Published:
Ruchika

Impactful leader of the Maryland Stem Cell Research Fund recognized

COLUMBIA, Md. (September 21, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced that Maryland Stem Cell Research Fund (MSCRF) executive director, Ruchika Nijhara, PhD, was named one of The Daily Record’s 2023 Influential Marylanders.

“Although a new addition to 1TEDCO, it’s already evident why Ruchika was chosen to be an Influential Marylander,” said Troy LeMaile-Stovall, TEDCO CEO. “Her dedication to supporting researchers is unwavering; she actively works to improve processes, support others and so much more. We are proud to be working with someone as talented and influential as Ruchika.”

 

Details
Published:
Seraxis

Leadership team expanded with addition of Chief Corporate Development Officer, Ted Hibben, a 25-year venture-stage business development biotherapeutic industry veteran Total venture funding tops $50M to date

GERMANTOWN, MD / ACCESSWIRE / September 21, 2023 / Seraxis Inc., a cell therapy company developing a pancreatic organoid cure to transform the lives of patients with Type 1 and insulin-requiring Type 2 diabetes, today announced the closing of the second tranche of its inaugural VC round to bring total equity investment in the company to over $50 million. Frazier Life Sciences, Polaris Partners, Eli Lilly and the JDRF T1D Fund participated in the step-up triggered by Seraxis' achieving the completion of preclinical milestones of Seraxis' novel pancreatic organoids, SR-02.

Details
Published:
Ronco

Ronco’s Global Pharmaceutical Experience Will Support the Next Chapter of Emmes’ Growth and Technology Enablement

Rockville, MD, September 20, 2023 – Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Peter Ronco has been named Chief Executive Officer, effective immediately.

Mr. Ronco succeeds Dr. Christine Dingivan, who will serve as a senior advisor to Executive Chairman Sastry Chilukuri, and Emmes’ Board of Directors.

Details
Published:
NanoChon

D.C.’s Nanochon LLC is raising $3.5 million to make it through the final leg of its journey to bring a 3D-printed knee cartilage implant to market.

The company has already raised $1.8 million toward the round, according to a Securities and Exchange Commission filing. The company said it plans to use the funds to begin human trials and ultimately get Food and Drug Administration approval for its 3D-printed implant.

 

Nanochon has raised $5 million since its founding in 2016 to fund the clinical trials needed to bring its medical device to market.

Details
Published:
VerImmune250

WASHINGTON, Sept. 20, 2023 /PRNewswire/ -- VerImmune Inc. ("VerImmune"), an early-stage biotechnology company specializing in the development of innovative products based on a novel Virus-inspired Particle (ViP™) technology platform, announced today the securing of an additional $3.125 million from follow-on Seed financing and a partnership milestone payment.

The follow-on financing was led by previous investor, Proxima VC, a specialist seed-to-growth healthcare venture capital firm with participation from other previous investors such as Gaingels, Mana Ventures and others. In addition to this financing, a milestone payment from Fosun Pharma USA was triggered by  the successful completion of a process development milestone.

Details
Published:
Childrens

Federal funding fosters development and commercialization of medical devices designed for children

WASHINGTON, D.C., Sept. 19, 2023 (GLOBE NEWSWIRE) -- To foster the development and commercialization of medical devices designed for children, the Food and Drug Administration (FDA) has awarded a nearly $7.5 million grant to the Alliance for Pediatric Device Innovation (APDI), a consortium led by Children’s National Hospital. The nonprofit group, which is one of five in the FDA’s Pediatric Device Consortia (PDC) program, will utilize the five-year grant to provide a platform of services, expertise and funding that supports pediatric innovators in bringing medical devices to the market that specifically address the needs of children. New in this cycle, APDI will provide expertise on evidence generation, including the use of real-world evidence (RWE), for pediatric device development.

Details
Published:
Forum Website

We're just ONE DAY away from the FREE 9th Annual BioHealth Capital Region Forum, and there's still time to register! Don't miss out on this incredible opportunity to join nearly 500 other registrants on September 19th and 20th. 🗓️

📍 Location: US Pharmacopeia (USP), 12601 Twinbrook Pkwy, Rockville, MD 20850
👔 Attire: Business/Business Casual
🚗 Parking: Paid-parking garage across the street or metered-street parking
🚇 Metro: Twinbrook Metro stop on the Red Line (8-minute walk)

🔬 Why Attend?

  • Network with esteemed government officials, academic leaders, and industry executives.
  • Explore new avenues for growth within the BioHealth Capital Region.
  • Engage in thought-provoking discussions and knowledge sharing.
  • Discover investment and partnership opportunities in the vibrant biohealth industry.

📈 The BioHealth Capital Region is a thriving hub of innovation and opportunity, boasting over 2,300 life science companies, 78 federal labs, and renowned academic institutions.

👉 Register now to be a part of this prestigious event and help shape the future of the BioHealth Capital Region!

Visit https://bit.ly/BHCRForum2023 to register now. 

Details
Published:
pqe250

PQE Group is excited to announce the opening of its newest office in Montreal, Quebec, Canada, marking a significant expansion for the company. The expansion aims to provide enhanced services to both existing and potential clients across various regions in Canada. The Greater Montreal area, located along North America's east coast, is renowned for its vibrant life sciences community, featuring prestigious universities, leading hospitals, and innovative life sciences companies. Notably, Quebec serves as a hub for the development and acceleration of artificial intelligence (AI), reflecting its forward-thinking approach to shaping the future. Canada's expertise in AI, characterized by its high-quality research, skilled workforce, and contributions to AI innovation on a global scale, has been a key source of inspiration for PQE Group.

Details
Published:
Crabby


Rockville, Maryland – September 13, 2023 – BioHealth Innovation, Inc. (BHI), a leading regional innovation intermediary, is thrilled to announce the five outstanding finalists for the 8th Annual BioHealth Capital Region Crab Trap competition. The Crab Trap is a competition designed to identify and showcase promising life sciences and biotechnology startups from around the world. These finalists have demonstrated exceptional innovation, vision, and potential to significantly impact the healthcare industry.

 

 

Details
Published:
Accelerate 2023 250

ARLINGTON, Va.--()--The Accelerate Investor Conference is back for its third year at George Mason University’s Arlington Campus, November 1-2, 2023. Spurring the region’s innovation and entrepreneurship engagement to a new level, the conference will showcase the Virginia, Maryland, and metropolitan DC region as a destination for business development, venture investment, and job creation.

Top venture firms from across North America participate to attend top keynotes and industry panels and watch 40+ high growth tech and life science companies pitch for their next round of capital. These cutting-edge startups compete for top prizes and are joined by 25 regional student teams presenting business concepts.

Details
Published:
Gain 250

BETHESDA, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that the Company has received approval from the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate a Phase 1 clinical study of its lead drug candidate GT-02287 in development for GBA1-Parkinson’s disease (GBA1-PD). Dosing in healthy volunteers to assess the safety and pharmacokinetics of GT-02287 is expected to begin in the near term.

Details
Published:
Altimmune 250

GAITHERSBURG, Md., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the completion of dosing (last subject last dose) in its 48-week Phase 2 MOMENTUM trial evaluating the efficacy and safety of pemvidutide in subjects with obesity or overweight. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and non-alcoholic steatohepatitis (NASH).

Details
Published:
oneweekbhcr

One week away from the 9th Annual BioHealth Capital Region Forum (https://bit.ly/BHCRForum2023), a cornerstone event for anyone involved in the biopharma sector. Scheduled for September 19th and 20th at the US Pharmacopeia in Rockville, Maryland, this year's forum promises to be an enriching experience for all attendees. Even better, thanks to the generosity of our sponsors, attendance is entirely free of cost!

A Gathering of Minds

The forum is a unique confluence of thought leaders, industry executives, academic pioneers, and government officials. This year, the keynote addresses promise to be particularly illuminating. Rachel King, the CEO of BIO, will speak on biotechnology's accomplishments and challenges in her talk titled "Biotechnology: What We've Accomplished and the Challenges Before Us." On the other end of the spectrum, Lance Liotta, Co-Director of the Center for Applied Proteomics and Molecular Medicine at George Mason University, will explore the cutting-edge intersection of AI and BioHealth in his keynote, "Hijacking Cellular Communications using AI Tools: A New Frontier in BioHealth."

Details
Published:
Supernus 250

ROCKVILLE, Md., Sept. 09, 2023 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announces the presentation of two posters at Psych Congress 2023 with new data showing improved efficacy in children ages 6 years and older with ADHD when Qelbree is added to a stimulant, as well as in adults with ADHD who undergo long-term treatment with Qelbree.

“While ADHD is recognized as one of the most common psychiatric diagnoses, affecting approximately 16.1 million individuals in the United States, patients are in need of alternative or additional options to stimulants that allow them to manage their symptoms with a safe and tolerable treatment option,” says Jonathan Rubin, Chief Medical Officer and Senior Vice President of Research & Development. “The new Qelbree data presented during Psych Congress 2023 reinforce the efficacy and safety of our novel nonstimulant treatment in addition to existing stimulant therapy in children ages 6 and older with ADHD and in a long-term setting in adults with ADHD.”

Details
Published:
NextCure250

BELTSVILLE, Md., Sept. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the publication of a review article in the online journal Frontiers in Immunology, highlighting the need for targeting tumor collagen in the extracellular matrix (ECM) in the tumor microenvironment to enhance anti-tumor immunity.

“Emerging data on the effects of dysregulated collagen in the ECM show that it modulates accessibility and activity of immune cells within the TME, leading to suboptimal oncology treatment outcomes,” said Solomon Langermann, Ph.D., NextCure’s chief scientific officer. “A key aspect of what we highlighted in this review is that an expanded understanding and cross-fertilization within the fields of tumor matrix biology, cancer biology, and immunology will contribute to improving the efficacy of cancer therapeutics. Importantly, it will enable the development of new classes of therapeutics to address the unmet needs of cancer patients who do not benefit from current therapies. This is a key focus of our ongoing NC410 clinical trial.”

Details
Published:
Resistance

The documentary-style film addresses the urgent global health crisis of antimicrobial resistance, which is causing widespread concern in the scientific and medical fields. The film highlights the dire consequences of this growing issue and showcases the relentless efforts of doctors, scientists, and experts who are working on innovative research and solutions to protect future generations.

https://www.youtube.com/watch?v=5U3k9ruszxI

Details
Published:
BHCR IC2 250

Your Invitation to apply to a Key Investment Event in Rockville, Maryland Awaits

There's still time if you haven't yet marked your calendar for the 6th Annual BioHealth Capital Region Investment Conference. The one-day event will also be held at the US Pharmacopeia (USP) in Rockville, Maryland, and is free to attend, thanks to our generous sponsors. Applications to attend are due by September 12th!

A Unique Investment Opportunity: September 21st

The Investment Conference brings together investors and companies seeking funding. With a strong track record of fostering successful financial engagements, this conference is an unparalleled opportunity for those eyeing transformative funding.

Details
Published:
BHCR Forum 250

Your Invitation to a Pivotal BioHealth Event in Rockville, Maryland Awaits

If you haven't yet marked your calendar for the 9th Annual BioHealth Capital Region Forum, it's not too late. The event will be held at the US Pharmacopeia (USP) in Rockville, Maryland, and is free to attend, thanks to our generous sponsors.

Two Days of In-Person BioHealth Exploration: September 19th and 20th

The Forum is just weeks away and promises an in-person experience under the theme "Global Breakthroughs for a Healthier Future." This cornerstone event offers industry experts, academic trailblazers, and government representatives a unique opportunity to reconnect in this “Top 3” BioPharma cluster.